Search results for "Log-rank test"

showing 10 items of 38 documents

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

2020

AbstractBackgroundHER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of new therapeutics has led to the approval of pertuzumab combined with trastuzumab and a taxane in first-line, and trastuzumab emtansine (T-DM1) in second-line. Thereby, evidence of T-DM1 efficacy following trastuzumab/pertuzumab combination is limited, with data from some retrospective reports suggesting lower activity. The purpose of the present study is to investigate T-DM1 efficacy in pertuzumab-pretreated and pertuzumab naïve HER2 positive ABC patients. We also aimed to provide evidence on the exposure to d…

0301 basic medicineOncologyCancer ResearchReceptor ErbB-2ApoptosisAdo-Trastuzumab EmtansineSettore MED/06chemistry.chemical_compound0302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsTumor Cells Culturedskin and connective tissue diseasesAged 80 and overMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisGene Expression Regulation NeoplasticSurvival RateOncology030220 oncology & carcinogenesisFemalePertuzumabmedicine.drugT-DM1 efficacymusculoskeletal diseasesAdultmedicine.medical_specialtyHER2+ breast cancer; Trastuzumab/pertuzumab blockade; T-DM1 efficacyBreast NeoplasmsAntibodies Monoclonal Humanizedlcsh:RC254-28203 medical and health sciencesSettore MED/04 - PATOLOGIA GENERALEInternal medicinemedicineBiomarkers TumorHumansneoplasmsAgedCell ProliferationRetrospective StudiesHER2+ breast cancer; T-DM1 efficacy; Trastuzumab/pertuzumab blockadeTaxanebusiness.industryResearchCancerHER2+ breast cancerTrastuzumabmedicine.diseaseTrastuzumab/pertuzumab blockadeBlockadeLog-rank test030104 developmental biologychemistryTrastuzumab emtansineCancer cellbusiness
researchProduct

MicroRNA-30a-5pme: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples

2020

Abstract Background The rising incidence of renal cell carcinomas (RCC) constitutes a significant challenge owing to risk of overtreatment. Because aberrant microRNA (miR) promoter methylation contributes to cancer development, we investigated whether altered miR-30a-5p expression associates with DNA promoter methylation and evaluated the usefulness as clear cell RCC (ccRCC) diagnostic and prognostic markers. Methods Genome-wide methylome and RNA sequencing data from a set of ccRCC and normal tissue samples from The Cancer Genome Atlas (TCGA) database were integrated to identify candidate CpG loci involved in cancer onset. MiR-30a-5p expression and promoter methylation were quantitatively a…

0301 basic medicineOncologyClear cell renal cell carcinomaCancer Researchmedicine.medical_specialty610Urinelcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinemicroRNADiagnosisMedicineDNA methylationReceiver operating characteristicmicroRNAbusiness.industryResearchBiomarkermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisLog-rank testClear cell renal cell carcinoma030104 developmental biologyOncologyCpG site030220 oncology & carcinogenesisDNA methylationbusinessClear cellJournal of Experimental & Clinical Cancer Research : CR
researchProduct

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience

2017

We addressed trastuzumab emtansine (T-DM1) efficacy in HER2+ metastatic breast cancer patients treated in real-world practice, and its activity in pertuzumab-pretreated patients. We conducted a retrospective, observational study involving 23 cancer centres, and 250 patients. Survival data were analyzed by Kaplan Meier curves and log rank test. Factors testing significant in univariate analysis were tested in multivariate models. Median follow-up was 15 months and median T-DM1 treatment-length 4 months. Response rate was 41.6%, clinical benefit 60.9%. Median progression-free and median overall survival were 6 and 20 months, respectively. Overall, no differences emerged by pertuzumab pretreat…

0301 basic medicineOncologyHER2 positivereal-worldmedicine.medical_specialtyHER2 positive; T-DM1; metastatic breast cancer; previous pertuzumab; real-worldHER2 positive; Metastatic breast cancer; Previous pertuzumab; Real-world; T-DM1; OncologyT-DM1Previous pertuzumabHER2 positive; metastatic breast cancer; previous pertuzumab; real-world; T-DM1; oncologyECOG Performance Statuslaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialSettore MED/04 - PATOLOGIA GENERALElawInternal medicineMedicineUnivariate analysisSettore MED/06 - ONCOLOGIA MEDICAbusiness.industryCancerprevious pertuzumabmedicine.diseaseMetastatic breast cancerMetastatic breast cancerHER2 positive; Metastatic breast cancer; Previous pertuzumab; Real-world; T-DM1Log-rank testtrastuzumab030104 developmental biologyOncologychemistryReal-worldTrastuzumab emtansine030220 oncology & carcinogenesisHER2 positive Metastatic breast cancer Previous pertuzumab Real-world T-DM1 Oncologymetastatic breast cancerPertuzumabbusinessmedicine.drugResearch Paper
researchProduct

Expression of claudin-5, claudin-7 and occludin in oral squamous cell carcinoma and their clinico-pathological significance

2015

Background: Claudin and occludin are the important tight junctions protein in human. The downregulation or upregulation of claudins and occludin might have a role in cancer development. The objective of this study was to investigate the expression of claudin-5, claudin-7 and occludin in oral squamous cell carcinoma (OSCC) and their relationships with the prognostically-related clinico-pathologic features. Material and Methods: Standard indirect immunohistochemical technique using anti-claudin-5, anti-claudin-7 and anti-occludin was performed in formalin-fixed paraffin-embedded tissue sections of 66 OSCC samples from Faculty of Dentistry, Chulalongkorn University. The positive cases were div…

0301 basic medicinePathologymedicine.medical_specialtyendocrine system diseasesOdontologíaBiologyOccludindigestive system03 medical and health sciences0302 clinical medicineDownregulation and upregulationmedicineClaudinGeneral DentistryUnivariate analysisOral Medicine and PathologyTight junctionurogenital systemResearch:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saluddigestive system diseasesLog-rank test030104 developmental biology030220 oncology & carcinogenesisCancer cellUNESCO::CIENCIAS MÉDICASImmunohistochemistrytissues
researchProduct

Resection with cryotherapy of colorectal hepatic metastases has the same survival as hepatic resection alone.

2001

Abstract Background Hepatic resection is well established as a potentially curative treatment for hepatic colorectal cancer metastases. However, only a small proportion of patients with liver metastases are suitable for resection because they either have extrahepatic disease, or the extent and/or the distribution of their hepatic disease would make excision impossible. We have previously described the use of cryotherapy for inadequate resection margins and lesions in the remaining lobe of the liver. Combining such cryodestructive techniques with resection offers the possibility of increasing the proportion of patients to whom potentially curative treatment can be offered. The aim of this st…

AdultMalePrognostic variablemedicine.medical_specialtyColorectal cancermedicine.medical_treatmentRectumCryotherapyCryosurgeryCryosurgerymedicineHepatectomyHumansSurvival rateAgedRetrospective StudiesAged 80 and overbusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurgeryLog-rank testSurvival Ratemedicine.anatomical_structureOncologySurgeryFemaleHepatectomybusinessColorectal NeoplasmsEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Developments in esophageal surgery for adenocarcinoma: a comparison of two decades

2007

Abstract Background The objective of this study was to examine outcomes in patients undergoing esophageal resection for adenocarcinoma at our institution during a 20-year period and, in particular, to address temporal trends in long-term survival. Methods Out of 470 patients who underwent esophagectomy for malignancy between September 1985 and September 2005, a total number of 175 patients presented with esophageal adenocarcinoma. Patients enrolled in this study included AEG (adenocarcinoma of the esophagogastric junction) type I tumors only. Time trends were studied comparing two decades, 9/1985 to 9/1995 (DI) and 10/1995 to 9/2005 (DII). Results The overall survival was significantly more…

AdultMalemedicine.medical_specialtyCancer ResearchTime FactorsEsophageal Neoplasmsmedicine.medical_treatmentAdenocarcinomaMalignancylcsh:RC254-282Disease-Free SurvivalSurgical oncologymedicineGeneticsHumansSurvivorsEsophagusSurvival analysisAgedNeoplasm StagingRetrospective Studiesbusiness.industryRetrospective cohort studyMiddle AgedPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseCombined Modality TherapySurvival AnalysisSurgeryEsophagectomyLog-rank testTreatment Outcomemedicine.anatomical_structureOncologyEsophagectomyLymph Node ExcisionAdenocarcinomaFemalebusinessResearch ArticleBMC Cancer
researchProduct

Clinicopathological evaluation and survival of patients with squamous cell carcinoma of the tongue.

2018

Background Early detection of oral cancer is the most effective means of reducing morbidity, complexity, and extent of treatment. This study evaluated the clinicopathological profile of epidermoid carcinoma of the tongue, including treatment and survival. Material and Methods This observational, retrospective cross-sectional study evaluated patients with squamous cell carcinoma of the tongue treated at the Dr. Luiz Antônio Hospital, Natal, Brazil, from January 2001 to December 2011. Survival variables were calculated using the Kaplan-Meier method and compared by log rank tests. Results Of the 412 patients diagnosed in this period, 298 (72.3%) were men; their mean age was 60.5 years, and 69.…

AdultMalemedicine.medical_specialtyGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineTongueInternal medicineCarcinomaMedicineHumansStage (cooking)General DentistrySurvival rateAgedRetrospective StudiesAged 80 and overOral Medicine and Pathologybusiness.industryResearchCancerRetrospective cohort study030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseTongue NeoplasmsLog-rank testSurvival Ratestomatognathic diseasesmedicine.anatomical_structureCross-Sectional StudiesOtorhinolaryngologyEpidermoid carcinoma030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASCarcinoma Squamous CellSurgeryFemalebusinessMedicina oral, patologia oral y cirugia bucal
researchProduct

Surgical treatment of primary gastrointestinal stromal tumors (GISTs): Management and prognostic role of R1 resections

2020

Abstract Background Surgery represents the best treatment for primary gastrointestinal stromal tumors (GISTs). The aim of this study is to analyse outcomes of surgical management in order to evaluate the influence of microscopically R1 margins on survival and recurrence in patients affected by GISTs. Methods The study reviewed retrospective data from 74 patients surgically treated for primary GISTs without metastasis at diagnosis. Clinical and pathological findings, surgical procedures, information about follow up and outcomes were analyzed. Results Recurrence rate was low and no patients died in the R1 group during the follow up period. The difference in recurrence free survival for patien…

AdultMalemedicine.medical_specialtyGastrointestinal Stromal TumorsPrognosiMetastasisPositive microscopic margins03 medical and health sciences0302 clinical medicineHumansMedicineIn patientGastrointestinal stromal tumors (GISTs)Surgical treatmentPathologicalGISTsAgedRetrospective StudiesAged 80 and overGiSTbusiness.industryMargins of ExcisionGeneral MedicineMiddle AgedSurgical proceduresPrognosismedicine.diseaseSurgeryLog-rank test030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologySurgeryNeoplasm Recurrence LocalPositive microscopic marginbusinessGISTThe American Journal of Surgery
researchProduct

FA01.02: THE EFFECT OF POSTOPERATIVE COMPLICATIONS AFTER MIE ON LONG-TERM SURVIVAL: A RETROSPECTIVE, MULTI-CENTER COHORT STUDY.

2018

Abstract Background Esophagectomy has a high incidence of postoperative morbidity. Complications lead to a decreased short-term survival, however the influence of those complications on long-term survival is still unclear. Most of the performed studies are small, single center cohort series with inconclusive or conflicting results. Minimally invasive esophagectomy (MIE) has been shown to be associated with a reduced postoperative morbidity. In this study, the influence of complications on long-term survival for patients with esophageal cancer undergoing a MIE were investigated. Methods Data was collected from the EsoBenchmark database, a collaboration of 13 high-volume centers routinely per…

AdultMalemedicine.medical_specialtyTime FactorsDatabases FactualEsophageal Neoplasmsmedicine.medical_treatmentAnastomotic LeakKaplan-Meier EstimateSingle Center03 medical and health sciencesPostoperative Complications0302 clinical medicineSDG 3 - Good Health and Well-beingmedicineHumansMinimally Invasive Surgical ProceduresAgedRetrospective Studiesbusiness.industryIncidence (epidemiology)GastroenterologyRetrospective cohort studyGeneral MedicineMiddle AgedEsophageal cancermedicine.diseaseSurgeryEsophagectomyLog-rank testTreatment OutcomeEsophagectomy030220 oncology & carcinogenesisCohortFemale030211 gastroenterology & hepatologybusinessCohort study
researchProduct

Elective nephron sparing surgery for renal cell carcinoma larger than 4 cm.

2007

Elective nephron sparing surgery is established as an alternative to radical nephrectomy for renal cell carcinoma if tumors are small (4 cm or less, stage T1a). We compared outcomes in patients with renal cell carcinoma 4 cm or less (small) vs more than 4 cm (large) who were treated with nephron sparing surgery.Between 1979 and 2006, 618 patients underwent elective nephron sparing surgery at our institution. Of these patients 474 (76.7%) had renal cell carcinoma, which was 4 cm or less in 372 (78.5%) and more than 4 cm in 102 (21.5%). Followup was 4.7 (range 0.1 to 23.9) years for small and 4.7 (range 0.1 to 24.1) years for large tumors. Cancer specific survival and local recurrence free su…

Adultmedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyNephrectomyRenal cell carcinomaparasitic diseasesmedicineCarcinomaHumansStage (cooking)Survival rateCarcinoma Renal CellAgedRetrospective StudiesAged 80 and overKidneybusiness.industryNephronsMiddle Agedmedicine.diseaseNephrectomyKidney NeoplasmsSurgeryLog-rank testmedicine.anatomical_structureNephron sparing surgerybusinessThe Journal of urology
researchProduct